Overview
- Sanofi reported that efdoralprin alfa met all primary and key secondary endpoints in the ElevAATe Phase 2 study after eight months of dosing.
- Efdoralprin alfa given every three or four weeks produced a statistically greater mean increase in functional AAT within the normal range versus weekly plasma-derived augmentation therapy at week 32.
- The study showed higher average functional AAT concentrations and a greater percentage of days above the lower limit of normal, with a safety profile similar to plasma therapy.
- Sanofi has not released granular numerical data and plans a full presentation at an upcoming medical meeting, with an additional safety follow-up underway in an open-label extension.
- Analysts said the readout validates Sanofi’s $2.2 billion 2024 acquisition of Inhibrx and could lift consensus estimates, with the company citing a large, underdiagnosed AATD population.